Articles |
From the First Department of Medicine, Osaka University School of Medicine, Japan.
Correspondence to Masafumi Kitakaze, MD, PhD, First Department of Medicine, Osaka University School of Medicine, 22 Yamadaoka, Suita 565, Osaka, Japan. E-mail kitakaze{at}medone.med.osaka-u.ac.jp
Abstract Patients with atrial fibrillation have been reported to exhibit abnormal hemostasis. Since nitric oxide (NO) exerts antithrombotic effects and attenuates platelet function, we evaluated two indicators of plasma NO levels, the plasma levels of nitrite and nitrate (NOx), and the levels of cGMP in platelets. We also examined whether indicators of plasma NO levels were associated with abnormalities in parameters related to platelet function, blood coagulation, and fibrinolysis. We evaluated 45 patients with chronic sustained atrial fibrillation (33 men and 12 women, age range 63±2 years) compared with 45 sex- and age- (±2 years) matched nonhospitalized subjects with sinus rhythm. There were no significant differences between the two groups in the incidence of risk factors for stroke except for ischemic heart disease or in echocardiographic parameters. Plasma levels of NOx measured using the Greiss reagent (mean [interquartile range]: 15.6 [9.5 to 25.7] versus 24.1 [14.2 to 40.8] µmol/L, n=45) and the platelet cGMP levels (0.33 [0.16 to 0.67] versus 0.63 [0.31 to 1.29] pmol/109 platelets, n=9) were significantly (P<.05) lower in the patients with atrial fibrillation than in the control subjects. Plasma levels of D-dimer, ß-thromboglobulin, and fibrinogen were significantly (P<.05) higher in the patients with atrial fibrillation. The two groups did not differ as to the plasma levels of tissue plasminogen activator or plasminogen activator inhibitor-1. Our findings suggest that a decrease in plasma NO levels may account for the hemostatic abnormalities observed in patients with atrial fibrillation.
Key Words: atrial fibrillation nitrite and nitrate platelet cGMP levels hemostatic disorders
This article has been cited by other articles:
![]() |
M Guazzi and R Arena Endothelial dysfunction and pathophysiological correlates in atrial fibrillation Heart, January 15, 2009; 95(2): 102 - 106. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Goette, A. Bukowska, U. Lendeckel, M. Erxleben, M. Hammwohner, D. Strugala, J. Pfeiffenberger, F.-W. Rohl, C. Huth, M. P.A. Ebert, et al. Angiotensin II Receptor Blockade Reduces Tachycardia-Induced Atrial Adhesion Molecule Expression Circulation, February 12, 2008; 117(6): 732 - 742. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Freestone, A. Y. Chong, S. Nuttall, A. D. Blann, and G. Y. H. Lip Soluble E-selectin, von Willebrand Factor, Soluble Thrombomodulin, and Total Body Nitrate/Nitrite Product as Indices of Endothelial Damage/Dysfunction in Paroxysmal, Persistent, and Permanent Atrial Fibrillation Chest, October 1, 2007; 132(4): 1253 - 1258. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hammwohner, A. Ittenson, J. Dierkes, A. Bukowska, H. U. Klein, U. Lendeckel, and A. Goette Platelet Expression of CD40/CD40 Ligand and Its Relation to Inflammatory Markers and Adhesion Molecules in Patients with Atrial Fibrillation Experimental Biology and Medicine, April 1, 2007; 232(4): 581 - 589. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S. G. Conway, P. Buggins, E. Hughes, and G. Y. H. Lip Relationship of interleukin-6 and C-Reactive protein to the prothrombotic state in chronic atrial fibrillation J. Am. Coll. Cardiol., June 2, 2004; 43(11): 2075 - 2082. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Cai, Z. Li, A. Goette, F. Mera, C. Honeycutt, K. Feterik, J. N. Wilcox, S. C. Dudley Jr, D. G. Harrison, and J. J. Langberg Downregulation of Endocardial Nitric Oxide Synthase Expression and Nitric Oxide Production in Atrial Fibrillation: Potential Mechanisms for Atrial Thrombosis and Stroke Circulation, November 26, 2002; 106(22): 2854 - 2858. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kamath, A.D. Blann, and G.Y.H. Lip Platelets and atrial fibrillation Eur. Heart J., December 2, 2001; 22(24): 2233 - 2242. [PDF] |
||||
![]() |
W. M. Feinberg, L. A. Pearce, R. G. Hart, M. Cushman, E. S. Cornell, G. Y.H. Lip, and E. G. Bovill Markers of Thrombin and Platelet Activity in Patients With Atrial Fibrillation : Correlation With Stroke Among 1531 Participants in the Stroke Prevention in Atrial Fibrillation III Study Stroke, December 1, 1999; 30(12): 2547 - 2553. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Minamino, M. Kitakaze, S. Sanada, H. Asanuama, T. Kurotobi, Y. Koretsune, M. Fukunami, T. Kuzuya, N. Hoki, and M. Hori Increased Expression of P-Selectin on Platelets Is a Risk Factor for Silent Cerebral Infarction in Patients With Atrial Fibrillation : Role of Nitric Oxide Circulation, October 27, 1998; 98(17): 1721 - 1727. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |